BCL2 and colorectal cancer: According to another study, the combination of navitoclax (a preclinical B-cell CLL/lymphoma 2 (BCL2)/BCLXL inhibitor), afatinib and selumetinib potently induced cell death in comparison with monotherapy of these drugs, signifying a possible alternative treatment strategy for colorectal cancer patients [93].